Fusion IP

MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.

Mesuro is a technology company specializing in radio frequency equipment and device measurement solutions for the semiconductor industry. Founded on over a decade of research at Cardiff University's Institute of High Frequency and Communication's Engineering, Mesuro collaborates with leading companies in the RF communications sector to tackle significant technical challenges. The company provides device modeling, characterization, and optimization test services aimed at enhancing the performance of RF and microwave devices and amplifiers, thereby supporting advancements in design and manufacturing processes.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

Seren Photonics Limited specializes in the development and manufacture of semi-polar and non-polar Gallium Nitride (GaN) templates, which are essential for light-emitting diodes (LEDs), lasers, vertical-cavity surface-emitting lasers (VCSELs), and power switches. Based in Bridgend, United Kingdom, the company employs a proprietary manufacturing process to produce these templates, specifically growing semi-polar GaN on m-plane sapphire and non-polar GaN on r-plane sapphire. Their innovative technology significantly enhances light intensity in high-brightness LEDs, achieving increases in light generation ranging from 100% to 900% compared to untreated diodes. Founded in 2009, Seren Photonics has positioned itself to serve various lighting markets, including backlighting for laptops and televisions, signage, and architectural lighting. As of November 2016, it operates as a subsidiary of Fusion IP Sheffield Limited.

Seren Photonics Limited specializes in the development and manufacture of semi-polar and non-polar Gallium Nitride (GaN) templates, which are essential for light-emitting diodes (LEDs), lasers, vertical-cavity surface-emitting lasers (VCSELs), and power switches. Based in Bridgend, United Kingdom, the company employs a proprietary manufacturing process to produce these templates, specifically growing semi-polar GaN on m-plane sapphire and non-polar GaN on r-plane sapphire. Their innovative technology significantly enhances light intensity in high-brightness LEDs, achieving increases in light generation ranging from 100% to 900% compared to untreated diodes. Founded in 2009, Seren Photonics has positioned itself to serve various lighting markets, including backlighting for laptops and televisions, signage, and architectural lighting. As of November 2016, it operates as a subsidiary of Fusion IP Sheffield Limited.

MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.

Mesuro is a technology company specializing in radio frequency equipment and device measurement solutions for the semiconductor industry. Founded on over a decade of research at Cardiff University's Institute of High Frequency and Communication's Engineering, Mesuro collaborates with leading companies in the RF communications sector to tackle significant technical challenges. The company provides device modeling, characterization, and optimization test services aimed at enhancing the performance of RF and microwave devices and amplifiers, thereby supporting advancements in design and manufacturing processes.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

Mesuro is a technology company specializing in radio frequency equipment and device measurement solutions for the semiconductor industry. Founded on over a decade of research at Cardiff University's Institute of High Frequency and Communication's Engineering, Mesuro collaborates with leading companies in the RF communications sector to tackle significant technical challenges. The company provides device modeling, characterization, and optimization test services aimed at enhancing the performance of RF and microwave devices and amplifiers, thereby supporting advancements in design and manufacturing processes.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.